140 related articles for article (PubMed ID: 36088875)
1. Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone.
Hirata S; Mishiro K; Higashi T; Fuchigami T; Munekane M; Arano Y; Kinuya S; Ogawa K
Nucl Med Biol; 2022; 114-115():34-41. PubMed ID: 36088875
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Effects of Linker Modification on Tumor-to-Kidney Contrast of
Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
[No Abstract] [Full Text] [Related]
4. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
6. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparative study of a novel
Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
[No Abstract] [Full Text] [Related]
8.
Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203
[TBL] [Abstract][Full Text] [Related]
9.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a novel
Sui Y; Duan X; Zhang J; Chu Y; Yang X
Bioorg Med Chem Lett; 2023 Jul; 91():129382. PubMed ID: 37348571
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
13. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
15. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
16. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
Acar E; Bekiş R; Polack B
Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
18. Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging.
Li Y; Duan X; Xu H; Zhang J; Zhou H; Zhang X; Zhang J; Yang Z; Hu Z; Zhang N; Tian J; Yang X
Bioorg Med Chem; 2022 Jul; 66():116810. PubMed ID: 35580538
[TBL] [Abstract][Full Text] [Related]
19. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
